Key Drivers
- Cash runway
- Negative equity
- No revenue
AIAI Summary
INBX has moved from a speculative biotech story to a real binary catalyst setup with a credible FDA path for ozekibart and encouraging early clinical signals, but the stock remains a high-risk trade because it is still highly asset-concentrated, cash-burning, and likely dependent on approval or financing before the 2027 decision window.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash runway
- •Negative equity
- •No revenue
INBX has strong near-term liquidity and a solid cash runway, but persistent losses, zero revenue, negative equity, and rising liabilities make the outlook financially fragile.
Price Behavior
Key Price Behavior Insights:
- •Higher Lows
- •Rebound Active
- •Range Resistance
INBX has improved over the last month with higher lows and a recent rebound, but it remains range-bound and must clear $99–$100 to confirm upside continuation.
Sharp early-June selloff gave way to a modest recovery
Sentiment & News
Key News Insights:
- •BLA accepted
- •No filing issues
- •PDUFA set
Inhibrx's FDA filing acceptance for ozekibart in conventional chondrosarcoma marks a key regulatory step, with a PDUFA decision now set for April 14, 2027.
This is a positive near-term catalyst for INBX, as it de-risks the program at the filing stage and shifts focus to the FDA review timeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings